2025-521497-34-00RecruitingPhase 1
Long-term follow-up of patients treated with GD2IL18CART
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Sept 2026
Brief summary (registry, in English)
To evaluate long-term safety after treatment with GD2IL18CART
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 4 Jul 2025
- Start date
- 6 Oct 2025
- Lead sponsor
- Universitaet Muenster
- EU CT number
- 2025-521497-34-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- No exclusion criteria are defined for this long-term follow-up trial.
Who the study is looking for
- Patient underwent treatment with GD2IL18CART in the primary trial prior to enrollment into long-term follow-up.
- Patient and/or caregivers have provided informed consent at any time prior to the first trial-specific assessment
Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Erlangen AöR | Erlangen | Germany | Recruiting |
| Universitaetsklinikum Essen (AoR) | Essen | Germany | Recruiting |
| Universitaet Muenster | Muenster | Germany | Recruiting |
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.